SAMe for preventing liver injury from oxaliplatin
Part of Cancer, Digestive system, Heart & circulation clinical trials.
This study tests whether a supplement called SAMe can help prevent liver damage caused by the chemotherapy drug oxaliplatin, which is given before liver surgery for colorectal cancer that has spread to the liver.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage 4 colorectal cancer that has spread to the liver and can be removed with surgery.
- You are at least 18 years old.
- You are planning to have liver surgery after chemotherapy that includes a drug called oxaliplatin.
- You are able to take care of yourself (up and about at least half the day).
- You are not taking certain medications like Olanzapine or MAO inhibitors (some antidepressants).
- You do not have severe nerve damage, liver disease, or other serious health issues that would interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two targeted drugs (serplulimab and bevacizumab) to standard chemotherapy before surgery can improve outcomes for people with colorectal cancer that has spread to the liver. It is for those whose cancer has certain genetic features and is considered resectable.
This trial tests a combination of three chemotherapy drugs (liposomal irinotecan, oxaliplatin, and capecitabine) given directly into the liver blood vessel after surgery to remove colorectal cancer that has spread to the liver. The goal is to reduce the chance of cancer coming back.
This trial tests a new drug combination for people with advanced colorectal cancer that cannot be removed by surgery. It aims to see if the treatment can shrink tumors and help patients live longer.
This Phase 3 trial tests a treatment approach for colorectal cancer that cannot be removed with surgery at first but has spread only to the liver. It is intended for people whose tumor is RAS/BRAF “wild-type” and who are well enough to do daily activities, to see if the treatment can control the cancer better.
This Phase 3 trial tests whether an added “maintenance” treatment after liver surgery can help prevent colorectal cancer from coming back. It is only for people whose blood test (ctDNA) still shows signs of cancer after their operation.
This trial tests whether taking coenzyme Q10 (a natural substance) can help prevent nerve damage caused by the chemotherapy drug oxaliplatin in people with stage III colorectal cancer. If successful, it could reduce pain, numbness, or tingling during treatment.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.